Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Highnoon LaboratoriesKAR:HINOON -0.45%96 Operating Margin % is 25.01% as of Mar. 2026, which is 43% above its 10-year median of 17.54. GuruFocus rates KAR:HINOON with a GF Score™ of 96/100 and a GF Value™ of ₨1,019.72 (Fairly Valued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Highnoon Laboratories ranks better than 87.59% on this metric.
Highnoon Laboratories Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Highnoon Laboratories's Operating Margin % or its related term are showing as below:
KAR:HINOON'
s Operating Margin % Range Over the Past 10 Years
Min: 14.08 Med: 17.54 Max: 23.58
Current: 23.58
KAR:HINOON's Operating Margin % is ranked better than 87.59% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.57
vs KAR:HINOON: 23.58
Highnoon Laboratories's 5-Year Average Operating Margin % Growth Rate was 3.90% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Highnoon Laboratories Operating Margin % Related Terms
Highnoon Laboratories Operating Margin % Historical Data
* Premium members only.
The historical data trend for Highnoon Laboratories's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:HINOON vs LLY, JNJ, ABBV: Operating Margin % Comparison
For the Drug Manufacturers - General subindustry, Highnoon Laboratories's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Highnoon Laboratories Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Highnoon Laboratories's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Highnoon Laboratories's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Highnoon Laboratories (KAR:HINOON) has a Operating Margin % of 25.01% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Highnoon Laboratories and its competitors. This is 43% above median its historical median of 17.54. Over the past decade, Highnoon Laboratories' Operating Margin % has ranged from 14.08 to 23.58. According to the industry distribution chart, Highnoon Laboratories ranks #119 out of 959 companies in the Drug Manufacturers industry, placing it in the top 12.4%.
Is Highnoon Laboratories' Operating Margin % too high?
Highnoon Laboratories' current Operating Margin % of 25.01% is 43% above median its 10-year median of 17.54. Over the past 10 years, this metric has ranged from a low of 14.08 to a high of 23.58. The Drug Manufacturers industry median Operating Margin % is 7.57. Highnoon Laboratories' value of 25.01% is 230.4% above this industry median. Based on the distribution chart, Highnoon Laboratories ranks #119 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' Operating Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Highnoon Laboratories ranks #119 out of 959 companies for Operating Margin %. This places Highnoon Laboratories in the top 12% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.57. Highnoon Laboratories' value of 25.01% is 230.4% above this benchmark. Historically, Highnoon Laboratories' own Operating Margin % has ranged from 14.08 to 23.58 over the past decade. While the company's 10-year median is 17.54 vs. the industry median of 7.57, Highnoon Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.57, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Highnoon Laboratories's current Operating Margin % of 25.01% is 230.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Highnoon Laboratories and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Highnoon Laboratories's current Operating Margin % is 25.01%, which is 43% above median its own 10-year median of 17.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,019.72, compared to a current price of ₨961.21 — trading 5.7% below its estimated fair value. The current Operating Margin % is 25.01%, which is 43% above median its 10-year median of 17.54 and 230.4% above the Drug Manufacturers industry median of 7.57. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current Operating Margin % is 25.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?
Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued.
The current stock price of ₨961.21 is trading 5.7% below its estimated GF Value™ of ₨1,019.72.
GuruFocus considers Highnoon Laboratories to be Fairly Valued.
Key valuation signals for KAR:HINOON:
Operating Margin %: 25.01% (43% above median its 10-year median of 17.54)
GF Value™: ₨1,019.72 vs. price of ₨961.21 (5.7% below fair value)
Industry Position: 230.4% above the Drug Manufacturers median (#119 of 959)
No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score
Get the complete analysis for KAR:HINOON
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HINOON has been successfully added to your 
